supplemental table 1. oligonucleotide sequences used for mrna expression analysis by qpcr. primer...
DESCRIPTION
DE Supplemental Figure 1 FTRANSCRIPT
Supplemental Table 1. Oligonucleotide sequences used for mRNA expression analysis by qPCR.
Primer name
Forward Primer 5’- 3’ Reverse Primer 5’-3’
KLK3 5’-GTGCTTGTGGCCTCTCG-3’ 5’-AGCAAGATCACGCTTTTGTTC-3’
TMPRSS2 5’-CGCTGGCCTACTCTGGAA-3’ 5’-CTGAGGAGTCGCACTCTATCC-3’
AR 5’- AAGGCTATGAATGTCAGCCCA-3’ 5’-CATTGAGGCTAGAGAGCAAGGC-3’
SRC1 5’-TGCAGCAGAATGTCTTCCAG-3’ 5’-AAAGTTGGCCTCACCTTGG-3’
SRC2 5’-ACCTGGTAAGAAGGTGTATTCAGAAG-3’ 5’-TGCCTCTTAGCATAGGACACAGA-3’
SRC3 5’-TCAACCCACTTCCTTCAGAGA-3’ 5’-ACATACTCATGCCGCCTACC-3’
ROCK1 5’-GAAACAGTGTTCCATGCTAGACG-3’ 5’-GCCGCTTATTTGATTCCTGCTCC-3’
β-Actin 5’-CACCATGTACCCTGGCATT-3’ 5’-GTACTTGCGCTCAGGAGGAG-3’
B
Supplemental Figure 1
A
miR
-205
miR
-1
miR
-133
a
miR
-133
b
miR
-143
-5p
miR
-145
-3p
miR
-204
miR
-143
-3p
miR
-31
miR
-24-
1-5p
miR
-221
-3p
miR
-135
a-5p
miR
-222
-3p
0
5
10
15
miR
-221
-5p
Primary CancerNormal Prostate
mic
roR
NA
exp
ress
ion
(log2
)
***
*
***
***
***
***
***
**
***
***
***
***
Primary CancerNormal Prostate
mic
roR
NA
exp
ress
ion
(log2
)
***
***
*** **
***
***
* ** *
miR
-205
miR
-1
miR
-133
a
miR
-133
b
miR
-143
-5p
miR
-145
-3p
miR
-221
-5p
miR
-204
miR
-143
-3p
miR
-31
miR
-24-
1-5p
miR
-221
-3p
miR
-135
a-5p
miR
-222
-3p
4
6
8
10
12
C
mic
roR
NA
exp
ress
ion
(log2
)
Primary CancerNormal Prostate
***
***
*** * ** *
* ** *
***
*
miR
-205
miR
-1
miR
-133
a
miR
-133
b
miR
-143
-5p
miR
-145
-3p
miR
-221
-5p
miR
-204
miR
-143
-3p
miR
-31
miR
-24-
1-5p
miR
-221
-3p
miR
-135
a-5p
miR
-222
-3p
−10
−5
0
5
D E
Supplemental Figure 1
F
* p< 0.05 by one way ANOVA with Dunnsmultiple comparison test for each column
G
Supplemental Figure 1lo
gex
pre
ssio
no
fm
icro
RN
A
miR
-20
5
miR
-1
miR
-133
a
miR
-133
b
miR
-143
-5p
miR
-145
-3p
miR
-221
-5p
miR
-20
4
miR
-143
-3p
miR
-31
mIR
-24
-1-5
p
miR
-221
-3p
miR
-135
-a-5
p
miR
-222
-3p0
5
10
15Low Gleason Intermediate Gleason High Gleason
*
*
0 20 40 60 80 1001200.00.20.40.60.81.0
Top 75%Bottom 25%
p= 0.1211
BC
R-fr
ee s
urvi
val
miR-143-3p
Time (months)0 20 40 60 80 100120
0.0
0.20.40.60.81.0
Top 75%Bottom 25%
p= 0.0982
BC
R-fr
ee s
urvi
val
miR-204
Time (months)
0 20 40 60 80 100 1200.00.20.40.60.81.0
Top 75%Bottom 25%
p= 0.5056
BC
R-fr
ee s
urvi
val
miR-222-3p
Time (months)
Supplemental Figure 2
0 20 40 60 801001200.00.20.40.60.81.0
Top 75%Bottom 25%
p= 0.4976
BC
R-fr
ee s
urvi
val
miR-24-1-5p
Time (months)
Top 75%Bottom 25%
p= 0.6361
BC
R-fr
ee s
urvi
val
miR-143-5p
Time (months)0 20 40 60 80100120
0.00.20.40.60.81.0
Supplemental Figure 3
CPDB Pathways
p21
RTK
PI3
KIR
S1
PIP 2
PIP 3
PD
K1
mTO
RC
2A
KT
T308
S47
3
TSC
1/TS
C2
mTO
RC
1 p70S
6K4E
BP1
FO
XO
3A
p21
p27
BIM
S6
eiF4
E
PRA
S40
p53
CD
C2
Rb
CD
K4
A
R
SRC
3
PTE
N
Cel
l Cyc
le/G
1-S
Tran
sitio
n
INPP
4B
AR
SRC
3
BIM
CD
C2
CD
K4
p27
INPP
4B
p4EB
P1 S
65p4EB
P1 T
37/4
6
p53
pRB
S80
7/81
1p-
S6 S
240/
244
p-S6
S23
5/23
6p-p7
0S6K
PTEN
p-PR
AS4
0
Supplemental Figure 4 A
PaxillinP-CadherinYB-1KRASc-Metp53BP1YAPSMAD4Cyclin E1Notch1p-AKT(S473)FibronectinSrcp-c-Met (Y1235)Beclin
c-
alpha-catenin14-3-3 epsilonp27HER2Claudin-7p21IGFBP2E-CadherinFOXO3ap-AKT(T308)SmacPTCHBIMN-CadherinBcl-XBcl-xLp-EGFR(Y992)VASPCDK4PCNAp70S6KChk2eEF2Kc-RAFSTAT5aMEK1SNAIlp-4E-BP1(T70)4E-BP1MSH6TIGARARp-YB-1(S102)FAKp-4E-BP1(S65)TTF1p-S6(S240/S244)p-4E-BP1(T37/T46)p-S6(S235/236)p-Rb(S807/S811)Cyclin B1CDK1INPP4BChk1p-p90RSK(T359/S363)p-EGFR(Y1068)JNK2VEGFR2Rad51p-Chk1(S345)c-IAPIGF-1R-beta
miR135a-5pNT
miR31NT
p-YAP (S12)
CDK1c-Myc
p-EGFR(Y1068)
Cyclin B1
JNK2
NF2 p-Chk1 (S345)
Cl PARP Src
Chk2STAT5A
YAPMSH6
p-4EBP1(T37/T46)
p-4EBP1 (S65)pRb(S807/811)ARp-HER3 (Y1298)p-4EBP1 (T70)VASPNotch1TTF1INPP4BSmacFOXO3a
p-mTOR(S2448)
PTCHmTOR
IGF-1R-betac-Metp-PKCA(S657)PKCAKRAS
HER3Smad3Cyclin E1Rab11p27Bcl-xLStathminp-HER2(Y1248)eEF2
B C
Suppl Fig 4
miR 1NT
Smacp-NFkBp65(S536)p-p38(T180Y182)BIMIGFBP2Bcl-XRab11Alpha-cateninKRASp27Cyclin E1HER2eEF2Kp-p27(T198)MEK1E-CadherinClaudin-7p53BP1mTORACC1Beta-cateninCaspase 7PKC-alphaeEF2p-EGFR(Y1068)TIGARc-RAFp-Rb(S807/S811)Cyclin B1p-p90RSK(T359/S363)TTF1p-Chk1(S345)CDK4p-4E-BP1(T70)Rad51p-AMPK(T172)p-AKT(T308)p-YAP(S127)CDK1Notch1ARp-AKT(S473)p-4E-BP1(S65)c-MycNotch3Fibronectinp-4E-BP1(T37/T46)IGF-1R-betaSrcCyclin D1p-c-Jun(S73)Smad1p21PCNAChk2VASPDvl3Gab2SRC3
miR221-5pNTD E Suppl Fig 4
TTF1Dvl3Gab2p-c-Jun(S73)Chk2INPP4Bp-EGFR(Y1068)SRC3STAT5-alphaJNK2Smad1p-p90RSK(T359/S363)p-Chk1(S345)p-Rb(S807/S811)p38 MAPKp-GSK alpha-beta(S21/S9)p70S6Kp-p38(T180/Y182)
Cyclin B1p-GSK3(S9)
FibronectinSrcp-AKT(S473)p-4E-BP1(S65)AKTp-YAP(S127)VEGFR2ARp-AKT(T308)E-CadherinCaspase-3SmacRab11c-KITmTORBeta-cateninYB-1Caspase-7KRASClaudin-7IGFBP2p-YB-1(S102)p53BP1Collagen VIp-c-Met(Y1235)p-p27(T198)HER3Alpha-cateninPKC-alphaMIG-6p-EGFR(Y992)Notch1HER2B
miR 133aNT
miR 133bNT
F G Suppl Fig 4
miR 143-3pNT
miR 24-1-3pNTIH Suppl Fig 4
miR 145-3pNT
miR 205NTJ K Suppl Fig 4
miR 221-3pNT
miR 222-3pNT
L M Suppl Fig 4
Supplemental Figure 5
A
B
* p<0.05
*
*
* p<0.05
Supplemental Figure 6: Correlation w/ other Signatures
A
r =0.46p< 0.01
hsa-
miR
-31
si-AR (A) signature score
r =0.46p< 0.01
hsa-
miR
-133
asi-AR (A) signature score
r =0.46p< 0.01
hsa-
miR
-133
b
si-AR (A) signature score
r =-0.02p= 0.86
hsa-
miR
-135
a-5p
si-AR (A) signature score
r =0.35p< 0.01
hsa-
miR
-143
-5p
si-AR (A) signature score
r =0.40p< 0.01
hsa-
miR
-145
-3p
si-AR (A) signature score
r =0.27p= 0.01
hsa-
miR
-1
si-AR (A) signature score
r =0.23P=0.03
hsa-
miR
-204
si-AR (A) signature score
r =0.45p< 0.01
hsa-
miR
-205
si-AR (A) signature score
r =0.34p< 0.01
hsa-
miR
-221
-5p
si-AR (A) signature score
r =0.34p<0.01hs
a-m
iR-2
21-3
p
si-AR (A) signature score
r =0.41p< 0.01hs
a-m
iR-2
22-3
p
si-AR (A) signature score
Suppl Fig 6B
r =0.56p< 0.01
hsa-
miR
-133
asi-AR (B) signature score
r =0.56p< 0.01
hsa-
miR
-133
b
si-AR (B) signature score
r = 0.09p= 0.40hs
a-m
iR-1
35a-
5p
si-AR (B) signature score
r = 0.47p= <0.01hs
a-m
iR-1
43-5
p
si-AR (B) signature score
r = 0.51p< 0.01hs
a-m
iR-1
45a-
3p
si-AR (B) signature score
r = 0.39p< 0.01
hsa-
miR
-1
si-AR (B) signature score
r = 0.34p< 0.01
hsa-
miR
-204
si-AR (B) signature score
r = 0.43p< 0.01
hsa-
miR
-205
si-AR (B) signature score
r = 0.46p< 0.01
hsa-
miR
-221
-5p
si-AR (B) signature score
r = 0.50p< 0.01
hsa-
miR
-221
-3p
r = 0.47p< 0.01
hsa-
miR
-222
-3p
si-AR (B) signature scoresi-AR (B) signature score
r =0.42p< 0.01
hsa-
miR
-133
a
si-AR (B) signature score
Suppl Fig 6C
Genes induced by
miR135a
Genes suppressed by
miR135a
Suppl Fig 6D
Correlation of miR135a-induced gene expression changes with changes induced by AR (detected by using AR siRNAs A and B)
NES=-1.94 q<0.0181
Genes upregulated by AR
(downregulated by si-AR-A)
Enr
ichm
ent S
core
NES=-2.54 q<0.0001
Genes upregulated by AR
(downregulated by si-AR-B)
Enr
ichm
ent S
core
Genes induced by
miR135a
Genes suppressed by
miR135a
Supplemental Figure 7
NES=-1.8821q<0.0888
Chandran Metastasis Up
Enric
hmen
t Sco
re
Genes induced by miR-
135a-5p
Genes suppressed by miR-
135a-5p
Supplemental Figure 8
MIB miR133A1 miR1-2
PrEC
LNCaP
LNCaP
PrEC H3K4Me3
H3K27Me3
H3K4Me3
H3K27Me3
(0-50)
(0-50)
(0-50)
(0-50)
153 kb
Supplemental Figure 9
A
B
C
PrEC
LNCaP
LNCaP
PrECH3K4Me3
H3K27Me3
H3K4Me3
H3K27Me3
(0-70)
(0-70)
(0-30)
(0-30)
miR-221miR-222
27 kb
miR31HGmiR-31
H3K4Me3
H3K27Me3
H3K4Me3
H3K27Me3
PrEC
LNCaP
LNCaP
PrEC (0-85)
(0-85)
(0-50)
(0-50)
85 kb
Supplemental Figure 10
B
C
A
Supplemental Table 3. Evaluation of direct SiM-miRNA effects on the proteomic changes assayed via RPPA
Supplemental Table 2. Proteomic signature for 12 SiM-miRNAs transfected into LNCaP cells.
Supplemental Table 4. Prediction of SiM-miRNAs on steroid receptor coactivators.
Note: Using a union of five leading prediction algorithms: TargetScan, miRanda, PicTar, DianaLab, and miRDB, we queried whether the SiM-miRNAs could target p160 coactivators SRC1, SRC2 and SRC3. Table shows that SRC1 is predicted by 3 independent algorithms to be targeted by miR-135a-5p.
Supplemental Table 5. AGO HITS-CLIP and AGO PAR-CLIP analysis.
miRNA Site ReadsH3K4me3
PrEC
ReadsH3K4me3
LNCaP
P-value ReadsH3K27me
3 PrEC
ReadsH3K27me3 LNCaP
P-value
miR-135a-5p
chr1297856241-97859472
99/651 32/655 1.274e-08 45/663 98/843 0.003536
miR-221-5p
chrX45625956-45631024
486/785 32/392 4.203e-38 7/235 8/477 0.277
miR-1 chr1819319997-19322746
209/840 91/436 0.221 5/484 26/736 0.0082
miR-31 chr921554820-21560351
1234/2461
43/722 1.752e-67 26/392 188/1263 7.860e-05
Supplemental Table 6. Comparison of H3K4Me3 and H3K27Me3 signal at the miR-135a-5p, miR-221-5p, miR-1, and miR-31 loci in PrEC and LNCaP cells